NMP22 Bladder Check Test for Monitoring Bladder Cancer - Revised
INDUSTRY NEWS TAGS: Noridian
The NMP22 Bladder Check Test is used in the diagnosis and monitoring of bladder cancer. NAS will allow coverage and payment for this test when used to monitor bladder cancer between cystourethroscopy intervals.
Effective for dates of service on or after January 1, 2012, use the following codes:
• 86386 - Nuclear Matrix Protein 22(NMP22), qualitative and V10.51 - Personal history of malignant neoplasm of bladder
For DOS September 19, 2011 through December 31, 2011 use 88299 - Unlisted cytogenetic study on Part B claims, add the description "NMP22" in Item 19 of the CMS-1500 form or the electronic equivalent. For Part A claims, add this notation to the remarks screen and V10.51.
Noridian Administrative Services: Carrier/FI for Arizona, Alaska, Idaho, Oregon, Montana, North Dakota, South Dakota, Utah, Washington, Wyoming and Minnesota.